Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	72599-27-0
Formula :	C₁₀H₂₁NO₄
M.W :	219.28
SMILES Code :	O[C@H]1[C@H](O)[C@@H](CO)N(CCCC)C[C@@H]1O
Synonyms :	NB-DNJ; N-Butyldeoxynojirimycin; N‐butyldeoxynojirimycin
MDL No. :	MFCD00272581
InChI Key :	UQRORFVVSGFNRO-UTINFBMNSA-N
Pubchem ID :	51634

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H361
Precautionary Statements:	P501-P202-P201-P280-P308+P313-P405

RAW264.7 cells	>50 μM		Assess the inhibitory effect of Miglustat on glucosylceramide synthase (GCS). Results indicated no significant inhibition of GCS at 50 μM concentration.	J Am Chem Soc. 2022 Aug 17;144(32):14819-14827
Pompe disease fibroblasts	20 μM	1-3 days	Evaluate the stabilizing effect of Miglustat on recombinant human α-glucosidase (rhGAA). Results showed a two-fold increase in rhGAA activity after 3 days in fibroblasts treated with both rhGAA and Miglustat compared to those treated with rhGAA alone.	J Am Chem Soc. 2022 Aug 17;144(32):14819-14827
RAW264.7 cells	500 μM	4 days	To study the effect of Miglustat on osteoclast lipid raft organization and NFATc1 nuclear localization, results showed that Miglustat disrupted lipid raft function.	J Clin Invest. 2015 Jun;125(6):2279-92
Mouse bone marrow cells	5, 50, 500 μM	5 days	To evaluate the effect of Miglustat on osteoclast formation, results showed that Miglustat significantly inhibited osteoclast formation.	J Clin Invest. 2015 Jun;125(6):2279-92
Neonatal rat cardiac fibroblasts (NRCFs)	100 μM and 200 μM	24 hours	To evaluate the effect of Miglustat on ISO-induced cardiac fibroblast activation. Results showed that Miglustat significantly inhibited ISO-induced NRCFs proliferation and reduced the expression of fibrosis markers (such as PCNA, CTGF, Fn, Col-I, Col-III, and α-SMA).	Mol Med. 2025 Feb 11;31(1):55
Primary 409 cells	100 µM	72 hours	To evaluate the effect of Miglustat on GSL expression in primary cells, results showed a reduction in GD2 expression	Int J Mol Sci. 2023 Jun 8;24(12):9905
A549-ACE2 cells	100 μM	72 hours	Evaluate the anti-SARS-CoV-2 activity of Miglustat, showing EC90 of 100 μM	J Enzyme Inhib Med Chem. 2024 Dec;39(1):2289007
Human astrocytes	100 μM	24 hours	Miglustat suppresses the expression of Pla2g4 and pro-inflammatory genes in activated human astrocytes	Cell. 2019 Dec 12;179(7):1483-1498. e22
GBA1-PD iPSC-derived hDA neurons	100 μM	3 days	reduce GlcCer accumulation and restore the ratio of α-syn tetramers and related multimers	Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):798-803
SH-SY5Y cells	100 μM	3 days	reduce intracellular GlcCer levels and restore the ratio of α-syn tetramers and related multimers	Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):798-803
SF8628 cells	100 µM	72 hours	To analyze the effect of Miglustat on GSL expression, results showed a significant decrease in GD2 expression	Int J Mol Sci. 2023 Jun 8;24(12):9905
SF8628 cells	100 µM	72 hours	To assess the effect of Miglustat on cell proliferation, results showed no significant impairment in cell viability after 72 hours of treatment	Int J Mol Sci. 2023 Jun 8;24(12):9905

C57BL/6 mice	Multiple myeloma model	Oral gavage	50 mg/mouse/day	Once daily for 21 days	To evaluate the effect of Miglustat on myeloma bone disease, results showed that Miglustat significantly improved bone disease symptoms.	J Clin Invest. 2015 Jun;125(6):2279-92
C57BL/6J mice	ISO-induced cardiac fibrosis model	Oral	150 mg/kg and 300 mg/kg	Twice daily for 7 days	To evaluate the effect of Miglustat on ISO-induced cardiac dysfunction and fibrosis. Results showed that Miglustat improved ISO-induced cardiac dysfunction, reduced cardiac fibrosis areas, and decreased the expression of fibrosis markers.	Mol Med. 2025 Feb 11;31(1):55
NOD mice	Experimental autoimmune encephalomyelitis (EAE)	Oral	600 mg/kg	Daily until EAE progressive phase	Miglustat suppresses NOD EAE progression, reducing axonal loss, demyelination, and recruitment of pro-inflammatory monocytes to the CNS	Cell. 2019 Dec 12;179(7):1483-1498. e22
Mouse	Mcoln1−/− mouse model	Intraperitoneal injection	300 mg/kg body weight	Daily from P10-P21, then three times a week until the end of the study	To evaluate the effects of Miglustat on motor deficits, cerebellar microgliosis, and Purkinje cell loss in the MLIV mouse model. Results showed that Miglustat delays the onset and progression of motor deficits, delays cerebellar Purkinje cell loss, and reduces cerebellar microgliosis characteristic of MLIV disease.	Neurobiol Dis. 2017 Sep;105:257-270

{[proInfo.proName]}

CAS No.: 72599-27-0

{[proInfo.proName]}

CAS No.: 72599-27-0

Alternative Products

Product Details of Miglustat

Safety of Miglustat

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT02612129	Niemann-Pick Disease, Type C	Phase 2 Phase 3	Active, not recruiting	October 2020	United States, California ... More >> UCSF Benioff Children's Hospital Oakland Oakland, California, United States, 94609 United States, Minnesota Mayo Clinic Children's Center Rochester, Minnesota, United States, 55905 Denmark University Hospital Copenhagen (Rigshospitalet) Copenhagen, Denmark, 2100 France CHU de Montpellier Montpellier, France, 34295 Montpellier Cedex 5 Hôpital Trousseau Paris, France, 75571 PARIS Cedex 12 Germany Villa Metabolica Mainz Mainz, Germany, 55131 Dr. von Haunersches Kinderspital der Universität München Munich, Germany, 80337 Italy Ospedale Pediatrico Bambino Gesù Rome, Italy, 00165 Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia" di Udin Udine, Italy, 33100 Poland The Children´s Memorial Istitute Warsaw Warsaw, Poland, 04-730 Spain Hospital Vall D'Hebron Barcelona, Spain, 08035 Switzerland INSELSPITAL University Hospital Bern Bern, Switzerland, CH-3010 United Kingdom Birmingham Children's Hospital Birmingham, United Kingdom, B4 6NH Great Ormond Street Hospital London, United Kingdom, WC1N 3JH Less <<
NCT00000791	HIV Infections	Phase 2	Completed	-	United States, Alabama ... More >> Alabama Therapeutics CRS Birmingham, Alabama, United States United States, California USC CRS Los Angeles, California, United States, 90033 Stanford CRS Palo Alto, California, United States Ucsf Aids Crs San Francisco, California, United States, 94110 United States, Colorado University of Colorado Hospital CRS Aurora, Colorado, United States United States, Florida Univ. of Miami AIDS CRS Miami, Florida, United States United States, Illinois Northwestern University CRS Chicago, Illinois, United States, 60611 Rush Univ. Med. Ctr. ACTG CRS Chicago, Illinois, United States, 60612 Weiss Memorial Hosp. Chicago, Illinois, United States, 60640 Cook County Hosp. CORE Ctr. Chicago, Illinois, United States United States, Indiana Indiana Univ. School of Medicine, Infectious Disease Research Clinic Indianapolis, Indiana, United States Methodist Hosp. of Indiana Indianapolis, Indiana, United States United States, Missouri St. Louis ConnectCare, Infectious Diseases Clinic St. Louis, Missouri, United States, 63112 Washington U CRS St. Louis, Missouri, United States United States, New York SUNY - Buffalo, Erie County Medical Ctr. Buffalo, New York, United States, 14260 Beth Israel Med. Ctr. (Mt. Sinai) New York, New York, United States Univ. of Rochester ACTG CRS Rochester, New York, United States United States, North Carolina Unc Aids Crs Chapel Hill, North Carolina, United States, 27514 Wake County Health and Human Services CRS Raleigh, North Carolina, United States United States, Ohio Univ. of Cincinnati CRS Cincinnati, Ohio, United States United States, Pennsylvania Hosp. of the Univ. of Pennsylvania CRS Philadelphia, Pennsylvania, United States United States, Washington University of Washington AIDS CRS Seattle, Washington, United States, 98104 Less <<
NCT02675465	Pompe Disease	Phase 1 Phase 2	Recruiting	September 2019	United States, Arizona ... More >> Neuromuscular Research Centre Recruiting Phoenix, Arizona, United States, 85028 Contact: Kumaraswamy Sivakumar 480-314-1007 ext 6 ksiva@nrcaz.com Contact: Kristy Osgood 480-314-1007 ext 6 kosgood@nrcaz.com Principal Investigator: Kumaraswamy Sivakumar United States, California University of California Irvine Recruiting Orange, California, United States, 92868 Contact: Tahseen Mozaffar 714-456-2332 Mozaffar@uci.edu Contact: Marie Wencel 714-456-2525 mwencel@uci.edu Principal Investigator: Tahseen Mozaffar United States, Florida University of Florida Recruiting Gainesville, Florida, United States, 32610 Contact: Barry J Byrne 352-273-6563 bbyrne@ufl.edu Contact: Lee Kugelmann 352-273-6588 ekugelm@ufl.edu Principal Investigator: Barry Byrne United States, Georgia Emory University Division of Medical Genetics Completed Decatur, Georgia, United States, 30033 United States, Michigan Infusion Associates Recruiting Grand Rapids, Michigan, United States, 49525 Contact: Khan Nedd, MD 616-954-0600 khan.nedd@infusionassociates.com Contact: Katie May 616-818-4473 katie.may@infusionassociates.com Principal Investigator: Khan Nedd United States, Montana Great Falls Clinic, LLP Recruiting Great Falls, Montana, United States, 59405 Contact: Karl Guter 406-771-3311 karl.guter@gfclinic.com Contact: Jacob Decker 406-771-3373 jacob.decker@gfclinic.com Principal Investigator: Karl Guter United States, New Jersey Rutgers New Jersey Medical School Recruiting Newark, New Jersey, United States, 08103 Contact: Xue Ming 973-972-2922 mingxu@njms.rutgers.edu Contact: Eliana Obando-Jaramillo 973-972-5435 emo65@njms.rutgers.edu Principal Investigator: Xue Ming United States, North Carolina Duke University Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: Priya Kishnani 919-684-2036 priya.kishnani@dm.duke.edu Contact: Ela Stefanescu 919-681-4026 mihaela.stefanescu@duke.edu Principal Investigator: Priya Kishnani United States, Pennsylvania University of Pittsburgh Recruiting Pittsburgh, Pennsylvania, United States, 15213 Contact: Paula Clemens 412-648-9762 clempr@upmc.edu Contact: Gabriela A Niizawa 412-383-9775 niizawaga@upmc.edu Principal Investigator: Paula Clemens United States, Virginia Lysosomal & Rare Disorders Research & Treatment Center (LDRTC) Recruiting Fairfax, Virginia, United States, 22030 Contact: Ozlem Goker-Alpan, MD 571-308-1925 ogoker-alpan@ldrtc.org Contact: Jacqueline Fikry 703-261-6220 ext 105 jfikry@ldrtc.org Principal Investigator: Ozlem Goker-Alpan Australia, South Australia Womens & Childrens Hospital, Adelaide Active, not recruiting North Adelaide, South Australia, Australia, 05006 Germany University Children's Hospital Department of Neuropediatrics and Inborn Metabolic Disorders, St. Josefs-Hospital Recruiting Bochum, Germany, 44791 Contact: Peter Schwenkreis +49 (0) 176 55 12 95 38 peter.schwenkreis@bergmannsheil.de Contact: Rebecca Trost +49 234 3023139 rebecca.trost@bergmannsheil.de Principal Investigator: Schwenkreis Peter Friedrich-Baur-Institure, Dep of Neurology - University Munich Recruiting Munich, Germany, 80336 Contact: Benedikt Schoser +49 (0) 89 4400 57400 benedikt.schoser@med.uni-muenchen.de Contact: Stephan Wenninger +49 (0) 89 4400 57470 Stephan.Wenninger@med.uni-muenchen.de Principal Investigator: Benedikt Schoser Netherlands Erasmus Medical Center Recruiting Rotterdam, Netherlands Contact: A.T. van der Ploeg 31107037254 a.vanderploeg@erasmusmc.nl Contact: Jacqueline Hardon 31107037047 j.hardon@erasmusmc.nl Principal Investigator: A.T. van der Ploeg United Kingdom University Hospital Birmingham NHS Foundation Trust, Queen Elizabeth Medical Center Completed Birmingham, United Kingdom, B15 2TH Salford Royal NHS Foundation Trust Recruiting Salford, United Kingdom, M6 8HD Contact: Mark Roberts 0161-206-4365 mark.roberts@srft.nhs.uk Contact: Catherine Wilson 44- 01612064851 Catherine.Wilson@srft.nhs.uk Principal Investigator: Mark Roberts Less <<
NCT03729362	Pompe Disease (Late-onset)	Phase 3	Recruiting	January 2021	United States, Arizona ... More >> Neuromuscular Research Center Not yet recruiting Phoenix, Arizona, United States, 85028 United States, California University of California, Irvine Recruiting Irvine, California, United States, 92868 United States, Virginia Lysosomal and Rare Disorders Research Recruiting Fairfax, Virginia, United States, 22030 Less <<
NCT00316498	Niemann Pick Diseases	Phase 1	Completed	-	United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 United States, New York Columbia University New York, New York, United States, 10032-3784 United Kingdom Oxford GlycoSciences Ltd. Abingdon, United Kingdom Less <<
NCT00001993	HIV Infections	Phase 2	Completed	-	United States, Florida ... More >> Univ of Miami School of Medicine Miami, Florida, United States, 331361013 United States, Illinois Rush Presbyterian - Saint Luke's Med Ctr Chicago, Illinois, United States, 60612 United States, Indiana Infectious Diseases Research Clinic / Indiana Univ Hosp Indianapolis, Indiana, United States, 46202 United States, Ohio Ohio State Univ Hosp Clinic Columbus, Ohio, United States, 432101228 United States, South Carolina Julio Arroyo West Columbia, South Carolina, United States, 29169 United States, Washington Univ of Washington Seattle, Washington, United States, 981224304 Less <<
NCT00000692	HIV Infections	Phase 1	Completed	-	United States, California ... More >> Univ of California / San Diego Treatment Ctr San Diego, California, United States, 921036325 Stanford Univ School of Medicine Stanford, California, United States, 94305 United States, Florida Univ of Miami School of Medicine Miami, Florida, United States, 331361013 United States, Illinois Rush Presbyterian - Saint Luke's Med Ctr Chicago, Illinois, United States, 60612 United States, Massachusetts Harvard (Massachusetts Gen Hosp) Boston, Massachusetts, United States, 02114 United States, South Carolina Julio Arroyo West Columbia, South Carolina, United States, 29169 Less <<
NCT00041535	Gaucher Disease	PHASE2	COMPLETED	2007-03-21	National Institutes of Health ... More >>Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States\|Institute of Child Health, London, United Kingdom Less <<
NCT00194649	Contraception	Phase 4	Completed	-	United States, Washington ... More >> University of Washington Seattle, Washington, United States, 98195 Less <<
NCT01451879	-		Completed	-	United States, Florida ... More >> University of Florida Gainesville, Florida, United States, 32610 Less <<
NCT00002079	HIV Infections	Phase 2	Completed	-	United States, California ... More >> Dr Marcus Conant San Francisco, California, United States, 94115 Shared Med Research Foundation Tarzana, California, United States, 91356 United States, Florida Stratogen of South Florida Miami Beach, Florida, United States, 33140 Saint Joseph's Hosp / Infectious Disease Rsch Institute Tampa, Florida, United States, 33614 United States, Georgia West Paces Clinical Research Incoporated Atlanta, Georgia, United States, 30327 United States, Pennsylvania Dr Samuel W Golden Pittsburgh, Pennsylvania, United States, 15218 United States, Texas Dallas Veterans Administration Med Ctr Dallas, Texas, United States, 75216 Dr Daniel Barbero Fort Worth, Texas, United States, 76104 Park Plaza Hosp Houston, Texas, United States, 77004 Less <<
NCT00537602	Cystic Fibrosis	Phase 2	Terminated(Methodology applied... More >> did not meet all criteria required per guidelines) Less <<	-	Spain ... More >> Corporacio Parc Tauli / Parc Tauli Hospital Barcelona, Spain Less <<
NCT00672022	GM2 Gangliosidoses ... More >> Tay-Sachs Sandhoff Disease Less <<	Phase 3	Completed	-	United States, District of Col... More >>umbia Children's National Medical Center Washington, District of Columbia, United States, 20010 Less <<
NCT00945347	Cystic Fibrosis	Phase 2	Completed	-	Belgium ... More >> Cliniques Universitaires St Luc (Université Catholique de Louvain) 10 avenue Hippocrate Brussels, Belgium, 1200 Less <<
NCT01822028	Diarrhea	Phase 1	Completed	-	Canada, Ontario ... More >> BioPharma Services Inc. Toronto, Ontario, Canada, M9L 3A2 Less <<
NCT02030015	GM1 Gangliosidoses ... More >> GM2 Gangliosidoses Tay-Sachs Disease Sandhoff Disease Less <<	Phase 4	Recruiting	August 31, 2019	United States, Minnesota ... More >> University of Minnesota Recruiting Minneapolis, Minnesota, United States, 55455 Contact: Jeanine R. Jarnes, PharmD 612-626-5131 utzx0002@umn.edu Principal Investigator: Jeanine R. Jarnes, PharmD Sub-Investigator: Chester B. Whitley, MD, PhD Less <<
NCT00418847	Gangliosidoses GM2	Phase 2	Completed	-	Canada, Ontario ... More >> The Hospital for Sick Children Toronto, Ontario, Canada, M5G 1X8 Less <<
NCT00319046	Gaucher Disease Type 1	Phase 3	Completed	-	-
NCT00319046	-		Completed	-	-
NCT00742092	Cystic Fibrosis	Phase 2	Completed	-	Belgium ... More >> Universite Catholique de Louvain Brussels, Belgium, B-1200 Less <<
NCT02185651	Pompe Disease ... More >> Hypersensitivity Reaction Less <<	Phase 1	Terminated(Participants not in... More >>terested in enrolling.) Less <<	-	-
NCT00517153	Niemann-Pick Type C Disease	Phase 2	Completed	-	United States, New York ... More >> Columbia University Medical Center New York, New York, United States, 10032 Less <<
NCT01760564	Niemann-Pick Disease Type C	Phase 3	Completed	-	Taiwan ... More >> National Taiwan University Hospital Taipei, Taiwan Less <<
NCT02520934	Gaucher Disease	Not Applicable	Active, not recruiting	December 2018	Taiwan ... More >> National Taiwan University Hospital Taipei, Taiwan, 10041 Less <<
NCT02325362	Cystic Fibrosis	Phase 2 Phase 3	Completed	-	France ... More >> Assistance publique-Hôpitaux de Paris, Hôpital Cochin Paris, France, 75014 Less <<

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed